Key result
Increasing platelet counts significantly increased the percentage decrease of TEG amplitude at 30 and 60 minutes due to clot retraction, an effect attenuated by abciximab.
Why the study?
Does platelet count and abciximab pretreatment affect clot retraction versus fibrinolysis on thrombelastography?
Population
Platelet-poor plasma and platelet-rich plasma samples with increasing platelet counts (range, 50-1200 x 10/L)
Comparison
Increasing platelet count with or without… vs Native PPP or PRP samples without abciximab or tPA
Design
Preclinical
Authors
Loading...
TEG amplitude decreases may reflect clot retraction rather than fibrinolysis, distinguishable by abciximab; leaves open clinical translation beyond animal models.
Does platelet count and abciximab pretreatment affect clot retraction versus fibrinolysis on thrombelastography?
Decreases in thrombelastography amplitude at 30 and 60 minutes can represent platelet-mediated clot retraction rather than fibrinolysis, and this can be distinguished using abciximab pretreatment.
Katori et al. (2005) studied this question. Increasing platelet count with or without abciximab vs. Platelet-poor plasma (PPP) was evaluated on Percentage decrease of amplitude at 30 and 60 min after maximum amplitude. Increasing platelet counts significantly increased the percentage decrease of TEG amplitude at 30 and 60 minutes due to clot retraction, an effect attenuated by abciximab.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: